Vancouver-based Aspect Biosystems has raised an impressive USD $115 million in Series B funding, signaling a major step forward in the development of bioprinted tissue therapeutics.
The financing round was led by Dimension, a life sciences and technology-focused investment firm, with participation from new and returning investors including Novo Nordisk, Radical Ventures, InBC, and others.
Building on partnerships with the governments of Canada and British Columbia and a diabetes and obesity collaboration with Novo Nordisk, the funds will accelerate Aspect’s work on bioprinted tissue therapeutics. The company’s mission centers on delivering a groundbreaking class of cellular medicines and functional cures for serious metabolic and endocrine diseases.
The investment will also expand Aspect’s advanced tissue therapeutic platform, integrating AI-powered bioprinting, computational design, therapeutic cells, and innovative biomaterials.
“We are thrilled to partner with this mission-aligned investor syndicate,” said Tamer Mohamed, Founder and CEO of Aspect Biosystems. “Their support enables us to pursue disease-modifying treatments and transform patient outcomes.”
As part of the deal, Nan Li, Founder and Managing Partner at Dimension, joins Aspect’s Board of Directors. Li praised Aspect as a leader in multidisciplinary biotech innovation, highlighting its integration of tissue engineering, cell therapy, biomaterials, and robotics as key to advancing regenerative medicine.
Aspect’s advancements mark a transformative era in biotechnology, with this funding solidifying its role at the forefront of regenerative medicine.
Leave a Reply